Abstract
Adenovirus was originally used as a vector for gene therapy. In recent years, with the development of the next-generation vectors with increased safety and high immunogenicity to transgene products, its utility as a vaccine vector has continued to increase. Adenovirus-based vaccines are currently being tested not only to prevent various infectious diseases but also to be applied as cancer vaccines. In this review, I discuss the innate and adaptive aspects of the immunological characteristics of adenovirus vectors and further examine the current status of advanced adenovirus-based vaccine development. Various methods that can overcome the limitations of currently used adenoviruses as vaccine vehicles are also discussed. Through this study, I hope that vaccine development using adenovirus vectors will be expedited and more successful.
| Original language | English |
|---|---|
| Article number | e6 |
| Pages (from-to) | 1-11 |
| Number of pages | 11 |
| Journal | Immune Network |
| Volume | 21 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2021 |
Bibliographical note
Funding Information:This study was supported by a grant of the National Research Foundation (grant No. NRF-2018R1A2B6002388) and Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (grant No. HV20C0049).
Publisher Copyright:
© 2021. The Korean Association of Immunologists.
Keywords
- Adenovector
- Adenovirus
- Genetic vector
- Vaccine